应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02615 百利天恒
待上市 08-17 16:00:00
0.000
+0.000
--
最高
0.000
最低
0.000
成交量
0.00
今开
0.000
昨收
0.000
日振幅
0.00%
总市值
0.00
流通市值
0.00
总股本
4.22亿
成交额
0.00
换手率
0.00%
流通股本
4.22亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床
证券之星 · 08-02
每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床
百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准
证券之星 · 07-30
百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准
百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组
格隆汇 · 07-26
百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组
百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组
智通财经 · 07-26
百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组
每周股票复盘：百利天恒（688506）现大宗交易机构净买入1014.85万元
证券之星 · 07-26
每周股票复盘：百利天恒（688506）现大宗交易机构净买入1014.85万元
百利天恒跌6.27% 招商证券在历史大顶发研报强烈推荐
中金财经 · 07-24
百利天恒跌6.27% 招商证券在历史大顶发研报强烈推荐
百利天恒：伦康依隆妥单抗两项III期临床完成首例入组
财中社 · 07-23
百利天恒：伦康依隆妥单抗两项III期临床完成首例入组
7月21日百利天恒现1笔大宗交易 机构净买入1014.85万元
证券之星 · 07-21
7月21日百利天恒现1笔大宗交易 机构净买入1014.85万元
7月20日百利天恒涨7.41%，中欧医疗健康混合A基金重仓该股
证券之星 · 07-20
7月20日百利天恒涨7.41%，中欧医疗健康混合A基金重仓该股
百利天恒涨7.41%，开源证券二个月前给出“买入”评级
证券之星 · 07-20
百利天恒涨7.41%，开源证券二个月前给出“买入”评级
每周股票复盘：百利天恒（688506）食管癌适应症获批上市
证券之星 · 07-19
每周股票复盘：百利天恒（688506）食管癌适应症获批上市
食管鳞癌二线“无标准方案”困境终结？百利天恒创新药宜泽康获批给出新答案
每日经济新闻 · 07-17
食管鳞癌二线“无标准方案”困境终结？百利天恒创新药宜泽康获批给出新答案
百利天恒（688506）披露伦康依隆妥单抗/宜泽康食管癌适应症上市申请获得批准，7月16日股价下跌0.22%
证券之星 · 07-16
百利天恒（688506）披露伦康依隆妥单抗/宜泽康食管癌适应症上市申请获得批准，7月16日股价下跌0.22%
百利天恒：EGFR×HER3双抗药物适应症申请获批准
财中社 · 07-16
百利天恒：EGFR×HER3双抗药物适应症申请获批准
7月15日百利天恒涨9.69%，中欧医疗健康混合A基金重仓该股
证券之星 · 07-15
7月15日百利天恒涨9.69%，中欧医疗健康混合A基金重仓该股
百利天恒涨9.69%，开源证券二个月前给出“买入”评级
证券之星 · 07-15
百利天恒涨9.69%，开源证券二个月前给出“买入”评级
每周股票复盘：百利天恒（688506）回购股份863,015股
证券之星 · 07-12
每周股票复盘：百利天恒（688506）回购股份863,015股
一个月涨100元！谢治宇葛兰布局的赛道龙头，主升浪信号出现？
中金财经 · 07-10
一个月涨100元！谢治宇葛兰布局的赛道龙头，主升浪信号出现？
百利天恒：累计回购2亿元公司股份，回购方案已实施完毕
每日经济新闻 · 07-08
百利天恒：累计回购2亿元公司股份，回购方案已实施完毕
百利天恒（688506）披露股份回购进展公告，7月2日股价上涨4.88%
证券之星 · 07-02
百利天恒（688506）披露股份回购进展公告，7月2日股价上涨4.88%
公司概况
公司名称：
百利天恒
所属市场：
SEHK
上市日期：
--
主营业务：
公司是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。公司拥有两大业务板块,分别为创新生物药业务和化药制剂、中成药制剂业务板块。公司主要产品:丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
--
{"stockData":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1786953600000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"08-17 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1786930200000,1786939200000],[1786942800000,1786953600000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":299.4,"timestamp":1786950000000,"preClose":302,"halted":0,"volume":1942500,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/02615/wiki","defaultTab":"wiki","newsList":[{"id":"2656316804","title":"每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316804?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:29","pubTimestamp":1785605350,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，百利天恒报收于298.0元，较上周的311.0元下跌4.18%。本周关注点来自公司公告汇总：注射用T-Bren在胆道癌III期临床完成首例受试者入组来自公司公告汇总：注射用BL-B01D1获准开展晚期实体瘤临床试验公司公告汇总四川百利天恒药业股份有限公司自主研发的注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中开展的III期随机对照临床试验已完成首例受试者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","02615","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655873611","title":"百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655873611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655873611?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:19","pubTimestamp":1785406775,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药监局签发的《药物临床试验批准通知书》，自主研发的创新生物药注射用BL-B01D1(皮下注射)获批在晚期实体瘤患者中开展临床试验。注射用BL-B01D1（皮下注射）是在公司伦康依隆妥单抗/宜泽康（BLB01D1/iza-bren）的基础上开发的皮下制剂，有望缩短临床给药时长，提高给药便捷性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000029541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654063189","title":"百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654063189","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654063189?lang=zh_cn&edition=full","pubTime":"2026-07-26 15:59","pubTimestamp":1785052768,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","02615","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654639210","title":"百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654639210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654639210?lang=zh_cn&edition=full","pubTime":"2026-07-26 15:48","pubTimestamp":1785052138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的创新生物药注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中对比T-Bren与医生选择的化疗的III期随机对照临床试验已于近日完成首例受试者入组。据悉，T-Bren是一种靶向HER2的创新型ADC，具有同类最佳潜力，已在临床试验中展示出显著的抗肿瘤功效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK4231","MDTX","IBBJ","02615","91194","688506","ADC","BMED","NETL","BK4080","BK0239","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052322","title":"每周股票复盘：百利天恒（688506）现大宗交易机构净买入1014.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052322?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:11","pubTimestamp":1784999469,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，百利天恒报收于311.0元，较上周的313.0元下跌0.64%。本周，百利天恒7月22日盘中最高价报353.0元。百利天恒当前最新总市值1284.04亿元，在化学制药板块市值排名3/149，在两市A股市值排名143/5200。来自公司公告汇总：伦康依隆妥单抗用于治疗胆道癌III期临床试验完成首例受试者入组。交易信息汇总7月21日百利天恒现1笔大宗交易，机构净买入1014.85万元。已有2项适应症获批上市，另有1项上市申请已获受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700984","title":"百利天恒跌6.27% 招商证券在历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700984","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700984?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:44","pubTimestamp":1784882657,"startTime":"0","endTime":"0","summary":"中国经济网北京7月24日讯 百利天恒(688506.SH)今日收报311.00元，跌幅6.27%。\r\n\r\n 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。\r\n\r\n 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒(688506)：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。\r\n\r\n 国泰海通证券股份有限公司研究员余文心、廖博闻2025年9月12日发布研报《百利天恒(688506)：WCLC上公布全球BIC数据 IZA-BREN有望冲击一线市场》称，维持增持评级。\r\n\r\n (责任编辑：徐自立)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260724/32317000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0188","BK0276","BK1147","BK0239","02615","91194","688506","600999","BK0012","BK1564","06099","BK0028","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653403937","title":"百利天恒：伦康依隆妥单抗两项III期临床完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2653403937","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653403937?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:00","pubTimestamp":1784808000,"startTime":"0","endTime":"0","summary":"7月23日，百利天恒（688506）发布公告，公司自主研发的全球首创EGFR×HER3双抗ADC伦康依隆妥单抗/宜泽康（BL-B01D1/iza-bren）两项III期临床试验于近日分别完成首例受试者入组，涉及适应症为经内分泌治疗失败的晚期HR+HER2-乳腺癌和含铂化疗失败的局部晚期或转移性胆道癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233819152061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233819152061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","02615","91194","BK0239","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653514276","title":"7月21日百利天恒现1笔大宗交易 机构净买入1014.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653514276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653514276?lang=zh_cn&edition=full","pubTime":"2026-07-21 18:13","pubTimestamp":1784628817,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日百利天恒发生大宗交易，交易数据如下：大宗交易成交价格341.7元，成交2.97万股，成交金额1014.85万元，买方营业部为机构专用，卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。近三个月该股共发生1笔大宗交易，合计成交297.0手。该股在过去半年内已有共计1187.38万股限售解禁股上市，占公司总股本的2.88%。截至2026年7月21日收盘，百利天恒报收于341.7元，上涨1.64%，换手率0.68%，成交量2.82万手，成交额9.45亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100034496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652029680","title":"7月20日百利天恒涨7.41%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652029680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652029680?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:31","pubTimestamp":1784536312,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日百利天恒涨7.41%，收盘报336.2元，换手率0.77%，成交量3.18万手，成交额10.33亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共129家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.926，较上一交易日下跌7.65%，近一年上涨2.86%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","91194","02615","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652968732","title":"百利天恒涨7.41%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2652968732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652968732?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:31","pubTimestamp":1784536305,"startTime":"0","endTime":"0","summary":"今日百利天恒涨7.41%，收盘报336.2元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","688506","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237412","title":"每周股票复盘：百利天恒（688506）食管癌适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237412","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237412?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:34","pubTimestamp":1784396050,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，百利天恒报收于313.0元，较上周的310.9元上涨0.68%。本周，百利天恒7月16日盘中最高价报347.99元。该药为全球首创、全球首个且唯一获批上市的同类药物，中国为其首发上市国家。本次获批为该药在中国的第二项适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284485","title":"食管鳞癌二线“无标准方案”困境终结？百利天恒创新药宜泽康获批给出新答案","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284485","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652284485?lang=zh_cn&edition=full","pubTime":"2026-07-17 23:57","pubTimestamp":1784303878,"startTime":"0","endTime":"0","summary":"7月16日，百利天恒（SH688506，股价313.00元，市值1292.30亿元）宣布，其全球首创EGFR×HER3双抗ADC（抗体偶联药物）药物伦康依隆妥单抗（iza-bren，商品名：宜泽康）获国家药监局批准第二项适应证，用于治疗既往经PD-1/PD-L1抑制剂联合含铂化疗治疗失败的复发性或转移性食管鳞癌（ESCC）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607173811420694.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607173811420694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","BK0239","91194","06978","IBBQ","159992","688506","02615","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651440961","title":"百利天恒（688506）披露伦康依隆妥单抗/宜泽康食管癌适应症上市申请获得批准，7月16日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651440961","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651440961?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:05","pubTimestamp":1784210725,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，百利天恒报收于332.83元，较前一交易日下跌0.22%，最新总市值为1374.17亿元。该药为全球首创、全球首个且唯一获批上市的同类药物，中国为其首发上市国家。本次获批为该药在中国的第二项适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600039970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","02615","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449841","title":"百利天恒：EGFR×HER3双抗药物适应症申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449841","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651449841?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:09","pubTimestamp":1784200140,"startTime":"0","endTime":"0","summary":"7月16日，百利天恒（688506）发布公告，近日，公司收到国家药品监督管理局的《药品注册证书》，批准公司自主研发的全球首创EGFR×HER3双抗ADC药物伦康依隆妥单抗/宜泽康（BL-B01D1/iza-bren）用于食管癌晚期二线适应症的上市申请。这是全球首个且唯一获批上市的此类药物，同时也是在中国获批的第二项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163809191980.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163809191980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651453925","title":"7月15日百利天恒涨9.69%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651453925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651453925?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:23","pubTimestamp":1784103822,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日百利天恒涨9.69%，收盘报333.58元，换手率0.99%，成交量4.09万手，成交额13.42亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值2.002，较上一交易日上涨3.85%，近一年上涨11.19%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","159760","BK0239","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651453952","title":"百利天恒涨9.69%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651453952","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651453952?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:23","pubTimestamp":1784103814,"startTime":"0","endTime":"0","summary":"今日百利天恒涨9.69%，收盘报333.58元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","688506","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650152817","title":"每周股票复盘：百利天恒（688506）回购股份863,015股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650152817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650152817?lang=zh_cn&edition=full","pubTime":"2026-07-12 03:21","pubTimestamp":1783797669,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，百利天恒报收于310.9元，较上周的340.0元下跌8.56%。本周，百利天恒7月6日盘中最高价报355.28元。本周关注点公司公告汇总：百利天恒回购股份863,015股，占总股本0.21%。公司公告汇总四川百利天恒药业股份有限公司于2026年6月1日至2027年5月31日期间，通过集中竞价交易方式累计回购股份863,015股，占公司总股本的0.21%，回购最高价为314.95元/股，最低价为201.02元/股，支付资金总额19,994.53万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200001281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185708","title":"一个月涨100元！谢治宇葛兰布局的赛道龙头，主升浪信号出现？","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185708","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650185708?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:03","pubTimestamp":1783674181,"startTime":"0","endTime":"0","summary":"不过，从月线来看，百利天恒在6月录得涨幅23.25%的基础上，截至7月6日中午的涨幅约为11.07%；体现在股价层面，公司的股价从6月2日盘中低点大约200元一路上涨，7月2日盘中最高曾经达到353.88元。而因为披露回购事项，百利天恒的最新股东情况也浮出水面，6月1日时六只公募占据十大股东的超半数席位，其中名将葛兰管理的中欧医疗健康和谢治宇管理的兴全合润，分别增持和新进该股。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/10/20260710378530.jpeg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/10/20260710378530.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260710/32304287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1223083913.SGD","LU1223082519.USD","CDE","GDXJ","IBBQ","SIL","SGDM","91194","BMED","BK4017","XME","02615","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995526","title":"百利天恒：累计回购2亿元公司股份，回购方案已实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995526","media":"每日经济新闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649995526?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:51","pubTimestamp":1783511494,"startTime":"0","endTime":"0","summary":"百利天恒公告，公司于2026年6月1日审议通过回购方案，计划回购资金总额不低于1亿元且不超过2亿元，回购价格上限398元/股，用于员工持股计划或股权激励。截至公告日，公司已累计回购股份86.3万股，占总股本0.21%，实际回购金额2亿元，回购价格区间201.02元/股至314.95元/股，回购方案已实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798564595.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798564595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BK0239","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648683010","title":"百利天恒（688506）披露股份回购进展公告，7月2日股价上涨4.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648683010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648683010?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:07","pubTimestamp":1783001235,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，百利天恒报收于335.5元，较前一交易日上涨4.88%，最新总市值为1385.19亿元。该股当日开盘310.95元，最高353.88元，最低310.01元，成交额达17.43亿元，换手率为1.28%。近日，四川百利天恒药业股份有限公司发布《关于股份回购进展公告》。公告显示，公司于2026年6月1日召开董事会，审议通过以集中竞价交易方式回购股份的方案，回购期限为2026年6月1日至2027年5月31日，拟回购金额为10,000万元至20,000万元，回购价格不超过398元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200041804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baili-pharm.com","compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。公司拥有两大业务板块,分别为创新生物药业务和化药制剂、中成药制剂业务板块。公司主要产品:丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","exchange":"SEHK","name":"百利天恒","nameEN":"BIOKIN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,02615,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}